Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice and is associated with a nearly 5-fold increase in the risk of stroke. Warfarin has been the cornerstone of treatment to reduce stroke risk in AF patients for decades. Although effective in preventing thrombosis, warfarin is difficult to manage and is associated with a 1% to 7% yearly risk of major hemorrhage. Until recently, there were no effective oral alternatives to warfarin. Dabigatran etexilate, a direct thrombin inhibitor, was approved in 2010 for the reduction of stroke and systemic embolism in patients with nonvalvular AF, and the factor Xa inhibitor rivaroxaban was approved for a similar indication in 2011. Other late-stage orally administered agents that may be approved for this indication include apixaban and edoxaban; others at earlier stages of development will be discussed in this review as well. Nonpharmacological approaches to stroke prevention include left atrial appendage removal, ligation, or occlusion. This review examines advances in the management of stroke risk in AF patients, focusing on recently marketed and late-stage modalities. The advent of alternatives to warfarin for reducing stroke risk in AF patients may improve physicians' ability to offer safe and effective stroke prevention in all AF patients.

Original languageEnglish (US)
Pages (from-to)45-54
Number of pages10
JournalCritical Pathways in Cardiology
Volume11
Issue number2
DOIs
StatePublished - Jun 2012

Fingerprint

Warfarin
Atrial Fibrillation
Stroke
Atrial Appendage
Antithrombins
Risk Management
Embolism
Ligation
Cardiac Arrhythmias
Thrombosis
Hemorrhage
Physicians

Keywords

  • anticoagulation
  • atrial fibrillation
  • left atrial appendage

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation. / Bommer, William J.

In: Critical Pathways in Cardiology, Vol. 11, No. 2, 06.2012, p. 45-54.

Research output: Contribution to journalArticle

@article{639b89f94830498693b1815920a614e6,
title = "Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation",
abstract = "Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice and is associated with a nearly 5-fold increase in the risk of stroke. Warfarin has been the cornerstone of treatment to reduce stroke risk in AF patients for decades. Although effective in preventing thrombosis, warfarin is difficult to manage and is associated with a 1{\%} to 7{\%} yearly risk of major hemorrhage. Until recently, there were no effective oral alternatives to warfarin. Dabigatran etexilate, a direct thrombin inhibitor, was approved in 2010 for the reduction of stroke and systemic embolism in patients with nonvalvular AF, and the factor Xa inhibitor rivaroxaban was approved for a similar indication in 2011. Other late-stage orally administered agents that may be approved for this indication include apixaban and edoxaban; others at earlier stages of development will be discussed in this review as well. Nonpharmacological approaches to stroke prevention include left atrial appendage removal, ligation, or occlusion. This review examines advances in the management of stroke risk in AF patients, focusing on recently marketed and late-stage modalities. The advent of alternatives to warfarin for reducing stroke risk in AF patients may improve physicians' ability to offer safe and effective stroke prevention in all AF patients.",
keywords = "anticoagulation, atrial fibrillation, left atrial appendage",
author = "Bommer, {William J}",
year = "2012",
month = "6",
doi = "10.1097/HPC.0b013e31824d705a",
language = "English (US)",
volume = "11",
pages = "45--54",
journal = "Critical Pathways in Cardiology",
issn = "1535-282X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation

AU - Bommer, William J

PY - 2012/6

Y1 - 2012/6

N2 - Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice and is associated with a nearly 5-fold increase in the risk of stroke. Warfarin has been the cornerstone of treatment to reduce stroke risk in AF patients for decades. Although effective in preventing thrombosis, warfarin is difficult to manage and is associated with a 1% to 7% yearly risk of major hemorrhage. Until recently, there were no effective oral alternatives to warfarin. Dabigatran etexilate, a direct thrombin inhibitor, was approved in 2010 for the reduction of stroke and systemic embolism in patients with nonvalvular AF, and the factor Xa inhibitor rivaroxaban was approved for a similar indication in 2011. Other late-stage orally administered agents that may be approved for this indication include apixaban and edoxaban; others at earlier stages of development will be discussed in this review as well. Nonpharmacological approaches to stroke prevention include left atrial appendage removal, ligation, or occlusion. This review examines advances in the management of stroke risk in AF patients, focusing on recently marketed and late-stage modalities. The advent of alternatives to warfarin for reducing stroke risk in AF patients may improve physicians' ability to offer safe and effective stroke prevention in all AF patients.

AB - Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice and is associated with a nearly 5-fold increase in the risk of stroke. Warfarin has been the cornerstone of treatment to reduce stroke risk in AF patients for decades. Although effective in preventing thrombosis, warfarin is difficult to manage and is associated with a 1% to 7% yearly risk of major hemorrhage. Until recently, there were no effective oral alternatives to warfarin. Dabigatran etexilate, a direct thrombin inhibitor, was approved in 2010 for the reduction of stroke and systemic embolism in patients with nonvalvular AF, and the factor Xa inhibitor rivaroxaban was approved for a similar indication in 2011. Other late-stage orally administered agents that may be approved for this indication include apixaban and edoxaban; others at earlier stages of development will be discussed in this review as well. Nonpharmacological approaches to stroke prevention include left atrial appendage removal, ligation, or occlusion. This review examines advances in the management of stroke risk in AF patients, focusing on recently marketed and late-stage modalities. The advent of alternatives to warfarin for reducing stroke risk in AF patients may improve physicians' ability to offer safe and effective stroke prevention in all AF patients.

KW - anticoagulation

KW - atrial fibrillation

KW - left atrial appendage

UR - http://www.scopus.com/inward/record.url?scp=84861426256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861426256&partnerID=8YFLogxK

U2 - 10.1097/HPC.0b013e31824d705a

DO - 10.1097/HPC.0b013e31824d705a

M3 - Article

C2 - 22595814

AN - SCOPUS:84861426256

VL - 11

SP - 45

EP - 54

JO - Critical Pathways in Cardiology

JF - Critical Pathways in Cardiology

SN - 1535-282X

IS - 2

ER -